IL10RA and neoplasm: It should be highlighted that achieved by us the approx. 50% reduction of the relative level of IL-10R expression (in the DC/shIL-10R_1/TAg group) in relation to DC/TAg was sufficient to increase the ability of the modified DCs to activate a specific anti-tumor response.